Sutro Biopharma regains Nasdaq compliance amid cancer drug breakthroughs
Sutro Biopharma, a clinical-stage oncology company, has regained compliance with Nasdaq’s minimum share price rule. The firm specialises in developing advanced antibody drug conjugates (ADCs) for cancer treatment. Its recent stock futures performance follows a key corporate move to stabilise trading value.
Founded in 2003, Sutro Biopharma focuses on site-specific and novel-format ADCs. These therapies target large oncology markets where treatment options remain limited. The company’s pipeline includes both single- and dual-payload ADCs designed to improve patient outcomes.
The compliance news comes after Sutro’s strategic stock market consolidation. Its ADC programmes continue to advance in clinical development. The company remains focused on addressing unmet needs in cancer care.
